Johnson & Johnson JNJ

$285.75 +2.23 (0.79%)

Valuation

Market cap
682,520,576,000
Revenue TTM
$94,193,000,000
Net income TTM
$26,804,000,000
P/E (trailing)
26.33
P/E (forward)
25.22
Profit margin
28.46%
Debt to equity
0.44

Trading

Volume
6,291,200
Avg volume
7,238,710
Day's range
$281.68 – $288.11
Shares out
2,407,310,000
Stochastic %K
90%
Beta
0.22
Analysts
Moderate Buy
Price target
$281.64

Price

Company profile

Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of a range of products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as oncology, immunology, neuroscience, pulmonary hypertension, infectious diseases, and cardiovascular...

Show more

Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of a range of products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as oncology, immunology, neuroscience, pulmonary hypertension, infectious diseases, and cardiovascular and metabolism distributed through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use. The MedTech segment provides a portfolio of products used in the surgery, orthopedic, cardiovascular, and vision fields distributed through wholesalers, hospitals and retailers, and used in the professional fields by physicians, nurses, hospitals, eye care professionals and clinics. This segment also offers products and enabling technologies that support joint reconstruction, trauma, spine, sports related injuries, and others, as well as open, laparoscopic, and robotic surgical procedures; instrumentation, energy devices, stapling systems, wound closure, biosurgery products, and digital and robotic technologies; breast aesthetics and reconstruction; contact lenses under the ACUVUE brand; intraocular lenses for cataract surgery, and other products used in cataract and refractive procedures under the TECNIS brand. The company was founded in 1886 and is based in New Brunswick, New Jersey.

Industry
Drug Manufacturers - General
Sector
Healthcare
Phone
732 524 0400
Website
https://www.jnj.com
Address
One Johnson & Johnson Plaza, New Brunswick, United States

Latest news

Stocktwits

SellasgpsCurativeBAT11 Nov 14, 4:12 PM
$ABBV $BMY $JNJ $PFE $SLS 👇 ✌️🙏❤️‍🩹
0 replies
SellasgpsCurativeBAT11 Nov 14, 4:07 PM
$SLS $JNJ $PFE $BMY $ABBV I expect an Immediate BO of Sellas after GPS Regal Pivotal Registrational Phase 3 Study Transformative Data. My # 1 Pick is $JNJ as $JNJ Executives have been openly touting Sellas GPS Breakthrough. 2. ABBV Ventoclax will become Obsolete after GPS FDA approval. 3. BMY Onureg will become Obselete after GPS FDA approval. 4. Pfizer CEO Bourla close ties to Sellas CEO Dr. Stergiou. ✌️🙏❤️‍🩹
0 replies
Cloudchowdur Nov 14, 3:37 PM
$SLS $JNJ I like the looks of this gang, Happy Saturday!
1 replies
viggizags Nov 14, 3:20 PM
$SPY $BTC.X i still find it hillarious Woody Johnson coin just absolutely destroyed the performance of bitcoin the past 5 years. If you bought the high in 2021 you are now down 5000 bucks and $JNJ Woody Johnson coin up just an insane amount in terms of bitcoin over that 5 year period Woody Johnson coin the true coin not this buttcoins stuff. Store of wealth they said. Mike Failyor kicking bears asses they said meanwhile.....dude named Woody Johnson is king I love this shit, cant make it up.
0 replies
Techdamentals Nov 14, 2:45 PM
🟡 Fair value → 🔴 Overvalued Fair value isn’t fixed. $JNJ went from fair value to overvalued on Techdamentals on Oct 30. Why a range moves, in four minutes. Watch the video here 👇 techdamentals.com/why-it-moves?ref=st Educational, not advice.
0 replies
Gfywoody Nov 14, 2:08 PM
$JNJ I really hope you guys do a one for one share purchase of Sellas. I love dividends.
0 replies
Equireason Nov 14, 11:54 AM
$JNJ sitting near 52-week highs, but Q3 was lopsided: Innovative Medicine grew about three times faster than MedTech, and a large litigation charge nearly wiped out GAAP EPS for the quarter. The rally is basically a pharma story right now; MedTech still has to show it can pull its weight.
0 replies
TraderFlorida Nov 14, 11:16 AM
$JNJ - up $19.00 from next suggested buy entry. Projected price target $331.00 area.
1 replies